| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
4 Integrin as Targets for the Treatment of Experimental Autoimmune Encephalomyelitis1
Immunology Research Group, Department of Physiology and Biophysics, University of Calgary, Calgary, Alberta, Canada
There has been a great deal of interest in adhesion molecules as targets for the treatment of multiple sclerosis and other inflammatory diseases. In this study, we systematically evaluate 
4 integrin and P-selectin as targets for therapy in murine models of multiple sclerosis–for the first time directly measuring the ability of their blockade to inhibit recruitment and relate this to clinical efficacy. Experimental autoimmune encephalomyelitis was induced in C57BL/6 or SJL/J mice and intravital microscopy was used to quantify leukocyte interactions within the CNS microvasculature. In both strains, pretreatment with blocking Abs to either 4 integrin or P-selectin reduced firm adhesion to a similar extent, but did not block it completely. The combination of the Abs was more effective than either Ab alone, although the degree of improvement was more evident in SJL/J mice. Similarly, dual blockade was much more effective at preventing the subsequent accumulation of fluorescently labeled leukocytes in the tissue in both strains. Despite evidence of blockade of leukocyte recruitment mechanisms, no clinical benefit was observed with anti-adhesion molecule treatments or genetic deletion of P-selectin in the C57BL/6 model, or in a pertussis toxin-modified model in SJL/J mice. In contrast, Abs to 4 integrin resulted in a significant delay in the onset of clinical signs of disease in the standard SJL/J model. Despite evidence of a similar ability to block firm adhesion, Abs to P-selectin had no effect. Importantly, combined blockade of both adhesion molecules resulted in significantly better clinical outcome than anti-4 integrin alone.
This article has been cited by other articles:
|
|
 |
|
  B. Engelhardt Editorial: PSGL-1--the hidden player in T cell trafficking into the brain in multiple sclerosis? J. Leukoc. Biol., November 1, 2009; 86(5): 1023 - 1025. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Coisne, W. Mao, and B. Engelhardt Cutting Edge: Natalizumab Blocks Adhesion but Not Initial Contact of Human T Cells to the Blood-Brain Barrier In Vivo in an Animal Model of Multiple Sclerosis J. Immunol., May 15, 2009; 182(10): 5909 - 5913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bauer, C. Brakebusch, C. Coisne, M. Sixt, H. Wekerle, B. Engelhardt, and R. Fassler {beta}1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity PNAS, February 10, 2009; 106(6): 1920 - 1925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Stirling, S. Liu, P. Kubes, and V. W. Yong Depletion of Ly6G/Gr-1 Leukocytes after Spinal Cord Injury in Mice Alters Wound Healing and Worsens Neurological Outcome J. Neurosci., January 21, 2009; 29(3): 753 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. McDonald, E. F. McAvoy, F. Lam, V. Gill, C. de la Motte, R. C. Savani, and P. Kubes Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids J. Exp. Med., April 14, 2008; 205(4): 915 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Smith and S. R. Barnum Differential expression of {beta}2-integrins and cytokine production between {gamma}{delta} and {alpha}{beta} T cells in experimental autoimmune encephalomyelitis J. Leukoc. Biol., January 1, 2008; 83(1): 71 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Doring, M. Wild, D. Vestweber, U. Deutsch, and B. Engelhardt E- and P-Selectin Are Not Required for the Development of Experimental Autoimmune Encephalomyelitis in C57BL/6 and SJL Mice J. Immunol., December 15, 2007; 179(12): 8470 - 8479. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
